Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Angela Testi

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
BMC Health Services Research|January 3, 2009
A model to prioritize access to elective surgery on the basis of clinical urgency and waiting timeRoberto Valente, Angela Testi, Elena Tanfani, et al.
BMC Medical Informatics and Decision Making|May 19, 2015
Optimization and planning of operating theatre activities: an original definition of pathways and process modelingSimone Barbagallo, Luca Corradi, Jean de Ville de Goyet, et al.
Human Vaccines & Immunotherapeutics|May 11, 2016
Vaccinating Italian infants with a new multicomponent vaccine (Bexsero®) against meningococcal B disease: A cost-effectiveness analysisRoberto Gasparini, Paolo Landa, Daniela Amicizia, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
BMC Health Services Research|January 3, 2009
A model to prioritize access to elective surgery on the basis of clinical urgency and waiting timeRoberto Valente, Angela Testi, Elena Tanfani, et al.
BMC Medical Informatics and Decision Making|May 19, 2015
Optimization and planning of operating theatre activities: an original definition of pathways and process modelingSimone Barbagallo, Luca Corradi, Jean de Ville de Goyet, et al.
Human Vaccines & Immunotherapeutics|May 11, 2016
Vaccinating Italian infants with a new multicomponent vaccine (Bexsero®) against meningococcal B disease: A cost-effectiveness analysisRoberto Gasparini, Paolo Landa, Daniela Amicizia, et al.
Pageof 2